Does Rallies show Form 4 insider transactions for ACXP?

Yes. Rallies tracks ACXP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ACXP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACXP. It does not provide personalized investment advice.

ACXP (Acurx Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Acurx Pharmaceuticals, Inc. Common Stock (ACXP) is a publicly traded Healthcare sector company. As of May 21, 2026, ACXP trades at $1.93 with a market cap of $7.74M and a P/E ratio of -0.35. ACXP moved +0.00% today. Year to date, ACXP is -33.92%; over the trailing twelve months it is -77.18%. Its 52-week range spans $1.33 to $44.00. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces ACXP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ACXP stock inside the company?

Recent ACXP insider activity includes Scodari Joseph C bought 24.63K, Sailer Carl bought 24.63K, LUCI DAVID P bought 49.26K, Donohue James J. bought 9.85K, and DELUCCIA ROBERT J bought 49.26K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ACXP Key Metrics

Key financial metrics for ACXP
Metric	Value
Price	$1.93
Market Cap	$7.74M
P/E Ratio	-0.35
EPS	$-5.32
Dividend Yield	0.00%
52-Week High	$44.00
52-Week Low	$1.33
Volume	265
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-7.97M
Gross Margin	0.00%

Recent ACXP Insider Trades

Scodari Joseph C bought 24.63K (~$25.00K) on Jan 6, 2025.
Sailer Carl bought 24.63K (~$25.00K) on Jan 6, 2025.
LUCI DAVID P bought 49.26K (~$50.00K) on Jan 6, 2025.
Donohue James J. bought 9.85K (~$10.00K) on Jan 6, 2025.
DELUCCIA ROBERT J bought 49.26K (~$50.00K) on Jan 6, 2025.

Latest ACXP News

Acurx’s DNA pol IIIC Inhibitors Achieve MRSA Reduction and Preserve Gut Diversity — May 4, 2026
Acurx Pharmaceuticals Raises $7.1M Offering with 825,085 Shares and Warrants — Apr 16, 2026
Acurx Wins Korean Patent for DNA Polymerase IIIC Inhibitors, Expanding IP to Six Countries — Mar 30, 2026
Acurx Launches 20-Patient Ibezapolstat Trial Following 96% Phase 2 Cure Rate — Mar 9, 2026
Acurx Wins US Patent 12,534,470 for ACX-375C DNA Polymerase IIIC Inhibitors — Feb 24, 2026

ACXP Analyst Consensus

3 analysts cover ACXP: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.

Common questions about ACXP

Who is trading ACXP stock inside the company?: Recent ACXP insider activity includes Scodari Joseph C bought 24.63K, Sailer Carl bought 24.63K, LUCI DAVID P bought 49.26K, Donohue James J. bought 9.85K, and DELUCCIA ROBERT J bought 49.26K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ACXP?: Yes. Rallies tracks ACXP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ACXP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACXP. It does not provide personalized investment advice.